// App-Quantinova.ai

: Phase II Trial of Elotuzumab with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) in the Post-Daratumumab Progression Setting

Researchers

Presenter

  • Sikander Ailawadhi

Principal Investigators

  • Ricardo D Parrondo

  • Betsy LaPlant

  • Victoria R. Alegria

  • Jamie B Elliott

  • Taimur Sher

  • Aneel Paulus

  • Dustin Chapin

  • Keisha Heslop

  • Asher Chanan-Khan

  • Vivek Roy

Medical Centers

  • Mayo Clinic Comprehensive Cancer Center, Jacksonville, FL

  • Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL

  • Mayo Clinic, Jacksonville, FL

  • Department of Hematology-Oncology, Mayo Clinic, Jacksonville, FL

  • Division of Clinical Trials & Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • Creatinine

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pomalidomide

  • CC-4047

  • daratumumab Intravenous

  • Elotuzumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved